William K. Oh, MD

William K. Oh, MD, discusses the rationale for presenting the data for the phase III ENZAMET trial in a plenary session at the 2019 ASCO Annual Meeting. He says these data were significant because it was a large randomized clinical trial for the treatment of newly diagnosed patients with metastatic hormone-sensitive prostate cancer.

William K. Oh, MD, chief, Division of Hematology and Medical Oncology, professor of medicine and urology, Mount Sinai School of Medicine, discusses the use of abiraterone and docetaxel in patients with metastatic castration-resistant prostate cancer. 

William K. Oh, MD, Chief of the Division of Hematology and Medical Oncology, the Tisch Cancer Institute at Mount Sinai Medical Center, discusses the utility of cabazitaxel for prostate cancer.

William K. Oh, MD, discusses immunotherapies for the treatment of patients with prostate cancer.

William K. Oh, MD, Chief of the Division of Hematology and Medical Oncology, the Tisch Cancer Institute at Mount Sinai Medical Center, discusses the process of validating a whole-blood prognostic signature in metastatic castration-resistant prostate cancer (mCRPC).

William K. Oh, MD, professor of medicine, hematology and medical oncology, urology, The Mount Sinai Hospital, discusses a biomarker development trial of satraplatin in patients with metastatic castrate-resistant prostate cancer.

William K. Oh, MD, Chief of the Division of Hematology and Medical Oncology, the Tisch Cancer Institute at Mount Sinai Medical Center, discusses sequencing treatment in patients with metastatic castration resistant prostate cancer.